(secondQuint)Cetuximab + Gemox in Biliary Tract Cancer.

 Primary Objective(s) The primary objective of the study is to evaluate the best overall response of cetuximab in combination with gemcitabine and oxaliplatin (GEMOX) as first line treatment in patients with advanced or metastatic biliary tract cancer.

 Secondary Objectives The secondary objectives of this study are as follows: - toxicity - secondary resection rate - progression-free survival (PFS) - overall survival (OS).

 Cetuximab + Gemox in Biliary Tract Cancer@highlight

The aim of this prospective single-centre phase II study is to investigate the therapeutic efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in the palliative first line treatment of biliary tract cancer (BTC) patients.

